Ultra Nasdaq Biotechnology 2X ETF (BIB)

N/A +N/A (N/A)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume N/A
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.

MacroHard26
MacroHard26 Jun. 5 at 4:15 AM
$RVMD $SPY $BIB $LABU $XBI https://www.streetwisereports.com/article/2026/06/04/california-pharma-co-tests-breakthrough-cancer-drug-cuts-death-risk-60.html
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 4 at 8:49 PM
$LXRX 🚨 NEVER-BEFORE-SEEN DATA drops Sunday June 7 at ADA 2026. Pilavapadin Phase 1 renal PK study — first public presentation ever. Here's why this is HUGE: → DPNP patients almost universally have damaged kidneys (diabetes destroys them) → Every current pain drug — pregabalin, duloxetine, gabapentin — requires dose adjustments in kidney disease, creating prescribing nightmares → Pilavapadin? Renal function does NOT affect how this drug behaves in the body → No dose adjustment. No renal testing. Prescribe to virtually the entire DPNP population cleanly This removes the #1 real-world barrier to a new DPNP drug getting prescribed broadly. Clean FDA label. Massive commercial upside. Active partnership talks ongoing. Non-opioid. CNS-penetrant. Novel AAK1 mechanism. Presented by Dr. Rodica Pop-Busui — OHSU — independent world-class DPNP researcher. Not a Lexicon employee. NDA resubmission for sotagliflozin T1D also imminent — mid-2026. Two pipeline drugs. ~$245M market cap $BIB $VTRS $NVO
0 · Reply
MacroHard26
MacroHard26 Jun. 3 at 12:29 AM
$RVMD $LABU $XBI $BIB $SPY Revolution Medicines, Inc. has delivered unprecedented Phase 3 data for daraxonrasib in second-line metastatic pancreatic cancer, nearly doubling overall survival versus chemotherapy. RVMD's daraxonrasib reduced death risk by 60%, with a median OS of 13.2 months versus 6.6 months for chemotherapy, and showed a favorable safety profile. There is a strong clinical results and potential for $5BN+ peak PDAC revenues . In the overall population, the objective response rate was 31.6% with daraxonrasib compared with 11.2% for chemotherapy. Daraxonrasib reduced the risk of death by 60% compared with chemotherapy. No prior Phase III study in metastatic pancreatic cancer has demonstrated median overall survival exceeding 1 year in any line of therapy
0 · Reply
MacroHard26
MacroHard26 Jun. 2 at 2:53 PM
$RVMD $SPYD $BIB $XBI $RVMD https://youtu.be/d7NqRRbISBs?si=-XmyC_VGdJVfopqq
1 · Reply
MacroHard26
MacroHard26 Jun. 2 at 12:00 PM
$RVMD $XBI $BIB $SPY $LABU A 60% Survival in PANCREATIC CANCER is unheard off.. Definitely earn a Standing Ovation !!!! $RVMD 🔥 🔥
0 · Reply
MacroHard26
MacroHard26 Jun. 2 at 3:20 AM
$RVMD $SPY $XBI $BIB $ARKG More revolutionary studies ongoing. $RVMD
0 · Reply
MacroHard26
MacroHard26 Jun. 2 at 3:17 AM
$SPY $RVMD $XBI $BIB $LABU Pancreatic cancer treatment breakthrough !!! $RVMD
0 · Reply
MacroHard26
MacroHard26 Jun. 1 at 6:29 PM
$RVMD $SPY $$XBI $BIB $LABU $RVMD new drug Daraxonrasib, with huge Success in Pancreatic cancer trial awaiting fast track FDa approval is also being tried for Rectal cancer with RAS mutation. Huge upside from here !!!
0 · Reply
SemiRetiredBlueCollarGuy
SemiRetiredBlueCollarGuy May. 31 at 5:07 AM
21 Best Leveraged Equity ETFs SOXL = Direxion Daily Semiconductor Bull 3X ETF TQQQ - ProShares UltraPro QQQ TECL - Direxion Daily Technology Bull 3X ETF USD - ProShares Ultra Semiconductors QLD - ProShares Ultra QQQ ROM - ProShares Ultra Technology UPRO - ProShares UltraPro S&P500 SPXL - Direxion Daily S&P500 Bull 3X ETF SPUU - Direxion Daily S&P 500 Bull 2X ETF UDOW - ProShares UltraPro Dow30 SSO - ProShares Ultra S&P500 CURE - Direxion Daily Healthcare Bull 3X ETF RXL - ProShares Ultra Health Care UCC - ProShares Ultra Consumer Discretionary DDM - ProShares Ultra Dow30 $UXI - ProShares Ultra Industrials $MIDU - Direxion Daily Mid Cap Bull 3X ETF $UMDD - ProShares UltraPro MidCap400 $BIB - ProShares Ultra Nasdaq Biotechnology $UGE - ProShares Ultra Consumer Staples TNA - Direxion Daily Small Cap Bull 3X ETF https://x.com/MicahMcDonald8/status/2060947289037033584?s=20
0 · Reply
masterofcharts
masterofcharts May. 14 at 3:16 PM
$BIB
0 · Reply
Latest News on BIB
Here is a List of Small-Cap Biotech ETFs to Watch for Big Gains in 2026

2026-02-19T19:18:15.000Z - 3 months ago

Here is a List of Small-Cap Biotech ETFs to Watch for Big Gains in 2026

CRBU CRNX GNOM HRTS REGN VKTX VRTX

MacroHard26
MacroHard26 Jun. 5 at 4:15 AM
$RVMD $SPY $BIB $LABU $XBI https://www.streetwisereports.com/article/2026/06/04/california-pharma-co-tests-breakthrough-cancer-drug-cuts-death-risk-60.html
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 4 at 8:49 PM
$LXRX 🚨 NEVER-BEFORE-SEEN DATA drops Sunday June 7 at ADA 2026. Pilavapadin Phase 1 renal PK study — first public presentation ever. Here's why this is HUGE: → DPNP patients almost universally have damaged kidneys (diabetes destroys them) → Every current pain drug — pregabalin, duloxetine, gabapentin — requires dose adjustments in kidney disease, creating prescribing nightmares → Pilavapadin? Renal function does NOT affect how this drug behaves in the body → No dose adjustment. No renal testing. Prescribe to virtually the entire DPNP population cleanly This removes the #1 real-world barrier to a new DPNP drug getting prescribed broadly. Clean FDA label. Massive commercial upside. Active partnership talks ongoing. Non-opioid. CNS-penetrant. Novel AAK1 mechanism. Presented by Dr. Rodica Pop-Busui — OHSU — independent world-class DPNP researcher. Not a Lexicon employee. NDA resubmission for sotagliflozin T1D also imminent — mid-2026. Two pipeline drugs. ~$245M market cap $BIB $VTRS $NVO
0 · Reply
MacroHard26
MacroHard26 Jun. 3 at 12:29 AM
$RVMD $LABU $XBI $BIB $SPY Revolution Medicines, Inc. has delivered unprecedented Phase 3 data for daraxonrasib in second-line metastatic pancreatic cancer, nearly doubling overall survival versus chemotherapy. RVMD's daraxonrasib reduced death risk by 60%, with a median OS of 13.2 months versus 6.6 months for chemotherapy, and showed a favorable safety profile. There is a strong clinical results and potential for $5BN+ peak PDAC revenues . In the overall population, the objective response rate was 31.6% with daraxonrasib compared with 11.2% for chemotherapy. Daraxonrasib reduced the risk of death by 60% compared with chemotherapy. No prior Phase III study in metastatic pancreatic cancer has demonstrated median overall survival exceeding 1 year in any line of therapy
0 · Reply
MacroHard26
MacroHard26 Jun. 2 at 2:53 PM
$RVMD $SPYD $BIB $XBI $RVMD https://youtu.be/d7NqRRbISBs?si=-XmyC_VGdJVfopqq
1 · Reply
MacroHard26
MacroHard26 Jun. 2 at 12:00 PM
$RVMD $XBI $BIB $SPY $LABU A 60% Survival in PANCREATIC CANCER is unheard off.. Definitely earn a Standing Ovation !!!! $RVMD 🔥 🔥
0 · Reply
MacroHard26
MacroHard26 Jun. 2 at 3:20 AM
$RVMD $SPY $XBI $BIB $ARKG More revolutionary studies ongoing. $RVMD
0 · Reply
MacroHard26
MacroHard26 Jun. 2 at 3:17 AM
$SPY $RVMD $XBI $BIB $LABU Pancreatic cancer treatment breakthrough !!! $RVMD
0 · Reply
MacroHard26
MacroHard26 Jun. 1 at 6:29 PM
$RVMD $SPY $$XBI $BIB $LABU $RVMD new drug Daraxonrasib, with huge Success in Pancreatic cancer trial awaiting fast track FDa approval is also being tried for Rectal cancer with RAS mutation. Huge upside from here !!!
0 · Reply
SemiRetiredBlueCollarGuy
SemiRetiredBlueCollarGuy May. 31 at 5:07 AM
21 Best Leveraged Equity ETFs SOXL = Direxion Daily Semiconductor Bull 3X ETF TQQQ - ProShares UltraPro QQQ TECL - Direxion Daily Technology Bull 3X ETF USD - ProShares Ultra Semiconductors QLD - ProShares Ultra QQQ ROM - ProShares Ultra Technology UPRO - ProShares UltraPro S&P500 SPXL - Direxion Daily S&P500 Bull 3X ETF SPUU - Direxion Daily S&P 500 Bull 2X ETF UDOW - ProShares UltraPro Dow30 SSO - ProShares Ultra S&P500 CURE - Direxion Daily Healthcare Bull 3X ETF RXL - ProShares Ultra Health Care UCC - ProShares Ultra Consumer Discretionary DDM - ProShares Ultra Dow30 $UXI - ProShares Ultra Industrials $MIDU - Direxion Daily Mid Cap Bull 3X ETF $UMDD - ProShares UltraPro MidCap400 $BIB - ProShares Ultra Nasdaq Biotechnology $UGE - ProShares Ultra Consumer Staples TNA - Direxion Daily Small Cap Bull 3X ETF https://x.com/MicahMcDonald8/status/2060947289037033584?s=20
0 · Reply
masterofcharts
masterofcharts May. 14 at 3:16 PM
$BIB
0 · Reply
masterofcharts
masterofcharts May. 8 at 9:12 PM
$BIB https://www.wavegenius.com/p/deep-dive-bib-5yr-chart-breakout-3-of-3-targets-1-618-and-2-618
0 · Reply
jjon2121
jjon2121 May. 8 at 11:33 AM
$XBI $LABU $LABD $IBB $BIB Found 2 more buyout announcements. Roche/Pathai 5/7 1.05B https://www.bioworld.com/articles/730966-roche-to-acquire-pathai-for-up-to-1.05b Angelini/Catalyst 5/7 4B https://www.biopharmadive.com/news/angelini-catalyst-acquisition-cns-drugs/819591/
1 · Reply
jjon2121
jjon2121 May. 4 at 11:24 AM
$XBI $LABU $LABD $IBB $BIB Two more buyouts announced since the previous buyout list was posted. Esperion Therapeutics is being acquired by healthcare investment firm Archimed in a deal worth up to $1.1 billion. 5/1. UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases. 5/4 https://www.biopharmadive.com/topic/biotech/ That takes the total over 20B since 4/27. So where is the buyout boost? Previous Buyouts posted: Teva/Emalex 4/29 700M biopharmadive.com/news/teva... Chiesi/KalVista 4/29 1.9B biopharmadive.com/news/chie... Thermo Fisher/Astorg 4/28 1.075B bioworld.com/articles/73067... Don't forget Sun pharma/Organon 4/27 11.75B bioworld.com/articles/73078... Lilly/Ajax on 4/27 2.3b biopharmadive.com/news/lill...
2 · Reply
jjon2121
jjon2121 Apr. 29 at 7:09 PM
$XBI $LABU $LABD $IBB $BIB Buyouts out of the woodworks: Over 17B last 3 days. Since 4/17, S&P hasn't dropped any. XBI down 8% IBB down 6.5% BIB down 13.6%. Where are you MMs? Buyouts: Teva/Emalex 4/29 700M https://www.biopharmadive.com/news/teva-emalex-acquisition-deal-tourette-drug-biotech/818827/ Chiesi/KalVista 4/29 1.9B https://www.biopharmadive.com/news/chiesi-kalvista-deal-acquire-hereditary-angioedema-ekterly/818798/ Thermo Fisher/Astorg 4/28 1.075B https://www.bioworld.com/articles/730672-thermo-fisher-sells-microbiology-business-for-1b Don't forget Sun pharma/Organon 4/27 11.75B https://www.bioworld.com/articles/730787-sun-pharma-to-acquire-merck-spinoff-organon-for-11.75b Lilly/Ajax on 4/27 2.3b https://www.biopharmadive.com/news/lilly-ajax-deal-acquire-jak-myelofibrosis-drug/818523/
2 · Reply
jjon2121
jjon2121 Apr. 28 at 9:46 AM
$XBI $LABU $LABD $BIB $IBB 2 new buyout announcements for bio. One small, one big. Lilly/Ajax 2.3B https://stkt.co/UrHKF14S Sun Pharma/Organon 11.75B https://stkt.co/1RW3kXb7
3 · Reply
howardlindzon
howardlindzon Apr. 12 at 6:07 PM
I dont understand most of what elliot talks about on his newsletter the 'century of biology' but It Is a good read as ai enters the sector a lot to prove https://centuryofbio.com/p/eroom?utm_source=post-email-title&publication_id=323104&post_id=178897767&utm_campaign=email-post-title&isFreemail=true&r=ndh&triedRedirect=true&utm_medium=email $IBB $BIB
1 · Reply
howardlindzon
howardlindzon Apr. 12 at 12:17 AM
$BIB $IBB I have to think ai offres so many tailwinds to biotech not sure what other etf's cobver this space so chime In please
1 · Reply
Merlin333
Merlin333 Mar. 13 at 1:56 PM
I have been saying and will say it again on $IVVD shares are tight, very tight. $IBB $XBI $BIB $QQQ
0 · Reply
Merlin333
Merlin333 Mar. 12 at 1:17 PM
$IVVD These are stats I look for, sub-5 #Phase3 Active Positions Holders Shares Increased Positions 75 114,960,406 Decreased Positions 27 12,588,461 Held Positions 23 123,924,350 As you can see institutions were busy in Q4! $IBB $XBI $BIB $SPY
0 · Reply
Merlin333
Merlin333 Mar. 11 at 6:03 PM
$BIB $IBB $IVVD $QQQ $XBI Let’s goooooo Bulls
0 · Reply
Merlin333
Merlin333 Mar. 11 at 3:01 PM
$IVVD Massive Buying! Just saying $QQQ $IBB $XBI $BIB
0 · Reply